US Stock Market Move | Novavax, Inc. (NVAX.US) rose more than 4.5% and Q4 losses narrowed.

On Thursday, Novavax, Inc. (NVAX.US) stock price rose, with the stock up over 4.5% to $7.61 as of the time of writing. In the latest fourth quarter financial report, the company's losses narrowed, mainly due to reduced sales and management expenses related to the COVID-19 vaccine. Currently, the vaccine is still the only product being sold by Novavax, Inc. In the quarter ending December 31, the company's net loss was $81 million, compared to $178.3 million in the same period last year. Novavax, Inc.'s fourth quarter sales of the COVID-19 vaccine were only $49.8 million, a significant decrease of 80.2% compared to the previous year. Facing weak market demand, the company is relying on revenue growth from its partnership with Sanofi, while also accelerating the development of new vaccines.